BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
Investment Companies |
Flash note
Investment Companies |
Review
Investment Companies |
Update
Claude Mikkelsen
Director of IR
Daniel Koller
Head of investment management
Dr Silvia Siegfried-Schanz
Director of IR
Erich Hunziker
Chairman
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 0.0 | (10.5) | 3.3 |
Relative | (0.7) | (13.0) | (4.2) |
52 week high/low | CHF49.4/CHF35.6 |
In our last BB Biotech (BION) review note, published in May 2024, we noted that the biotech sector was eagerly awaiting some key milestones, the most important being Alnylam Pharmaceuticals’ late-stage clinical trial of vutrisiran for patients with ATTR cardiomyopathy, a deadly heart disease. Alnylam, which comprised 4.3% of BION’s portfolio at end March 2024, released very positive, statistically significant, Phase III trial results this week. Assuming regulatory clearance, Alnylam expects that vutrisiran has the potential to become the new standard of care for the treatment of this disease, driving substantial future growth for the company. These results may have favourable implications for sentiment across the broader global biotech sector, and for Ionis Pharmaceuticals, BION’s largest portfolio position, which is also developing gene-silencing technology.